The Food and Drug Administration plans to drop its longtime standard of requiring two rigorous studies for new drug approvals ...
FDA open to pooling data from ongoing Phase I/II studies of LX2006 with data from pivotal trial, and to earlier co-primary endpoint assessment, to support a Biologics License Application FDA approved ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results